Sichuan Hexie Shuangma Co (000935) Fair Value & Analysis
Financial Services · CN · Market cap 20.7B CNY
Analysis
Sichuan Hexie Shuangma Co (000935) currently trades at ¥25.67, while our model-based Fair Value estimate is ¥6.64 — implying the stock looks roughly 74.1% overvalued today. We read business quality at 94/100 (high quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Sichuan Hexie Shuangma Co., Ltd. engages in the manufacture and sale building material products in China. It offers cement, commercial clinker, and aggregates used for infrastructure, industrial park construction, municipal livelihood projects, commercial housing development, urban renewal, and rural revitalization. The company is also involved in biopharmaceutical research and development and production business; and private equity investment fund management business. In addition, the company engages in peptide API research and development, and production; peptide contract customization; customized research and development, and production business; and beauty peptide research and development, and production business. Further, it offers semaglutide, liraglutide, and tilpotide targeting major chronic diseases; and invest in manufacturing and new energy industries, including photovoltaics, chip design and manufacturing, consumer electronics, intelligent equipment, industrial automatio…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.